LPCN Lipocine Inc

Price (delayed)

$2.12

Market cap

$17.48M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.87

Enterprise value

$12.5M

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 9
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 22

Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery. Lipocine has drug candidates in development as well as drug candidates for ...

Highlights
Lipocine's EPS has shrunk by 123% YoY but it has increased by 4.6% QoQ
Lipocine's equity has increased by 27% YoY but it has decreased by 4.7% QoQ
LPCN's net income has shrunk by 163% YoY and by 3.6% QoQ
LPCN's revenue has dropped by 63% year-on-year and by 22% since the previous quarter

Key stats

What are the main financial stats of LPCN

LPCN stock price

How has the Lipocine stock price performed over time
Intraday
-1.85%
1 week
-1.85%
1 month
1.44%
1 year
-23.19%
YTD
-73.6%
QTD
-17.19%

Financial performance

How have Lipocine's revenue and profit performed over time
Revenue
$1.57M
Gross profit
$1.57M
Operating income
-$12.57M
Net income
-$11.85M
Gross margin
100%
Net margin
-755.1%
LPCN's net income has shrunk by 163% YoY and by 3.6% QoQ
The company's operating income has shrunk by 125% YoY and by 3.6% QoQ
LPCN's revenue has dropped by 63% year-on-year and by 22% since the previous quarter
The gross profit has dropped by 63% year-on-year and by 22% since the previous quarter

Price vs fundamentals

How does LPCN's price correlate with its fundamentals

Growth

What is Lipocine's growth rate over time

Valuation

What is Lipocine stock price valuation
P/E
N/A
P/B
0.8
P/S
11.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.96
Lipocine's EPS has shrunk by 123% YoY but it has increased by 4.6% QoQ
The P/B is 57% less than the last 4 quarters average of 1.9 and 45% less than the 5-year quarterly average of 1.5
Lipocine's equity has increased by 27% YoY but it has decreased by 4.7% QoQ
The price to sales (P/S) is 92% lower than the 5-year quarterly average of 137.0 and 32% lower than the last 4 quarters average of 16.6
LPCN's revenue has dropped by 63% year-on-year and by 22% since the previous quarter

Efficiency

How efficient is Lipocine business performance
The ROIC has plunged by 177% YoY but it has grown by 7% from the previous quarter
Lipocine's ROE has plunged by 174% YoY but it has increased by 3% from the previous quarter
LPCN's ROA has dropped by 163% year-on-year but it is up by 3% since the previous quarter
Lipocine's return on sales has decreased by 32% QoQ

Dividends

What is LPCN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LPCN.

Financial health

How did Lipocine financials performed over time
LPCN's total liabilities is up by 43% year-on-year but it is down by 18% since the previous quarter
Lipocine's total assets has increased by 28% YoY but it has decreased by 6% QoQ
LPCN's debt is 100% smaller than its equity
Lipocine's equity has increased by 27% YoY but it has decreased by 4.7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.